Gamgee Technologies
Gamgee Technologies provides the first end-to-end personalized cancer treatment protocol for dogs, using genomic sequencing and AI to design custom mRNA vaccines targeting each tumor's specific mutations. The company manages the entire workflow—from case review and tissue collection through vaccine creation and oncologist-administered treatment—and is currently running clinical trials in Australia with registrations of interest open worldwide.
- Biotechnology
- Healthcare Technology
- Drug Discovery & Therapeutics
- Pet Technology
- Artificial Intelligence
Funding
Raised to date
$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Dogs diagnosed with cancer often face limited treatment options, especially when standard protocols like surgery, chemotherapy, and immunotherapy fail. Personalized treatments that target the specific mutations driving each dog's tumor are typically inaccessible, requiring specialized expertise that most pet owners do not have.
Solution
Gamgee provides the first end-to-end personalized cancer treatment protocol for dogs. The company manages the entire workflow: reviewing each case, coordinating with the dog's veterinarian to collect a tissue sample, sequencing the tumor genome, and designing a personalized mRNA vaccine that targets the specific mutations driving that cancer. The treatment is administered by a veterinary oncologist, and Gamgee monitors the dog's response. The underlying science—genomic sequencing, protein modeling, and mRNA synthesis—already exists; Gamgee's innovation is making it accessible through a structured, managed pathway for any dog owner.
Target Audience
Primary customers are dog owners whose pets have been diagnosed with cancer, particularly those who have not responded to conventional treatments, as well as veterinary oncologists who administer the personalized protocols.
Features
- Personalized mRNA vaccine design based on each tumor's unique genetic mutations identified through genomic sequencing
- End-to-end workflow covering case review, tissue sample collection, lab analysis, vaccine creation, and oncologist-administered treatment
- AI-driven pipeline that reads the tumor, identifies the mutations that matter, and designs the vaccine to match
- Collaboration with research institutions including UNSW, the University of Queensland, and the Garvan Institute
- Currently running clinical trials in Australia with open registrations of interest worldwide
- Built on machine learning expertise, using AI to map mutations and design vaccine protocols